
            <div class="content-section" id="section-68">
                <span class="en">
                    <h2>Antineoplastic Agents: Mechanisms of Action and Toxicity</h2><br>#<h2>Key Concepts</h2>

<ul><br><li><strong>Pentostatin</strong>: A drug used to treat cancer, combining with fludarabine can cause toxicity including myelosuppression, immunosuppression, nausea, vomiting, headache, lethargy, and fatigue.</li><br><li><strong>Methotrexate (MTX)</strong>: An antifolate agent used to treat various types of cancer, its mechanism of action involves inhibiting dihydrofolate reductase (DHFR) leading to depletion of reduced folates necessary for purine and pyrimidine biosynthesis.</li><br><li><strong>Pemetrexed (MTA, Alimta)</strong>: A pyrrolopyrimidine analog of folic acid with antifolate activity, used to treat mesothelioma, NSCLC, colorectal cancer, bladder cancer, and lung cancer. Its mechanism of action involves inhibiting thymidylate synthase (TS) resulting in inhibition of thymidylate and DNA synthesis.</li><br><li><strong>Trimetrexate (TMTX, Neutrexin)</strong>: A folate antagonist used to treat colorectal cancer, head and neck cancer, and NSCLC. Its mechanism of action involves inhibiting thymidylate synthesis. Resistance can occur by increased expression of the target enzyme, decreased binding affinity for the target enzyme, or decreased intracellular drug transport.</li><br><li><strong>Hydroxyurea (Droxia, Hydrea)</strong>: An antimetabolite drug used to treat myelogenous leukemia, ovarian cancer, and essential thrombocytosis. Its mechanism of action involves inhibiting DNA biosynthesis by inhibiting ribonucleotide reductase.</li><br></ul>

<p>#<h2>Summary</h2></p>

<ul><br><li>The antineoplastic agents discussed in this section include pentostatin, methotrexate, pemetrexed, trimetrexate, and hydroxyurea.</li><br><li>Each agent has a unique mechanism of action involving inhibition of specific enzymes or pathways necessary for DNA synthesis and cell division.</li><br><li>Resistance to these agents can occur through various mechanisms including increased expression of the target enzyme, decreased binding affinity for the target enzyme, or decreased intracellular drug transport.</li><br></ul>

<p>#<h2>Important Information</h2></p>

<ul><br><li>The toxicity profiles of these antineoplastic agents include myelosuppression, immunosuppression, nausea, vomiting, headache, lethargy, and fatigue.</li><br><li>Hydroxyurea has been shown to increase the toxicity of 5-FU and may enhance the effectiveness of some antimetabolite HIV drugs.</li><br></ul>




                </span>
                <span class="ar">
                    <h2>[استراتيجيات تصميم الأدوية]</h2><br>#<h2>المفاهيم الرئيسية</h2>

<ul><br><li><strong>الدواء 1</strong>: الشرح</li><br><li><strong>الدواء 2</strong>: الشرح</li><br></ul>

<p>#<h2>ملخص</h2></p>

<ul><br><li>النقطة الرئيسية 1: كل من هذه الدوائين لها آلية عمل فريدة invol-ving inhibition of specific enzymes or pathways necessary for DNA synthesis and cell division.</li><br><li>النقطة الرئيسية 2: كل من هذه الدوائين يسبب سمية مختلفة بما في ذلك الاضطراب في نخاع العظم، والتمييز عن الأنسجة، والنقي.</li><br></ul>

<p>#<h2>معلومات مهمة</h2></p>

<ul><br><li>حقيقة أساسية 1: جميع هذه الدوائين يمكن أن تؤدي إلى سمية مختلفة.</li><br></ul><br><li>حقيقة أساسية 2: كل من هذان الدواينين قد يسبب زيادة في سمية ل5-FU.</li>


                </span>
            </div>
            